A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable.
Alessio CortelliniMelissa BersanelliSebastiano ButiKatia CannitaDaniele SantiniFabiana PerroneRaffaele GiustiMarcello TiseoMaria MichiaraPietro Di MarinoNicola TinariMichele De TursiFederica ZorattoEnzo VeltriRiccardo MarconciniFrancesco MalorgioMarco RussanoCecilia AnesiTea ZeppolaMarco FilettiPaolo MarchettiAndrea BotticelliGian Carlo Antonini CappelliniFederica De GalitiisMaria Giuseppa VitaleFrancesca RastelliFederica PergolesiRossana BerardiSilvia RinaldiMarianna TudiniRosa Rita SilvaAnnagrazia PiredduFrancesco AtzoriRita ChiariBiagio RicciutiAndrea De GiglioDaniela IaconoAlain GelibterMario Alberto OcchipintiAlessandro ParisiGiampiero PorzioMaria Concetta FargnoliPaolo Antonio AsciertoCorrado FicorellaClara NatoliPublished in: Journal for immunotherapy of cancer (2019)
Overweight could be considered a tumorigenic immune-dysfunction that could be effectively reversed by ICIs. BMI could be a useful predictive tool in clinical practice and a stratification factor in prospective clinical trials with ICIs.